Hospital Clinico Universitario De Valladolid

The Hospital Clinico Universitario De Valladolid is actively evaluating new strategies to lower the burden of cardiovascular disease. Trials focus on patients with coronary artery disease, atherosclerotic disease, acute myocardial infarction, atrial fibrillation and related conditions, aiming to test novel antiplatelet regimens, lipid‑lowering agents and anti‑inflammatory therapies.

• Optimization of antiplatelet therapy after transcatheter aortic valve implantation
• IL‑6 inhibition with a monoclonal antibody to reduce major adverse cardiovascular events
• Continuing versus stopping statins after intracerebral hemorrhage
• Evaluation of novel PCSK9 inhibitor for high‑risk patients without prior MI
• Management strategies for spontaneous coronary artery dissection

With 97 trials and 82 investigators, the site contributes significantly to advancing cardiovascular care in Europe.

Research at the endocrinology department targets metabolic and hormonal disorders such as type 2 diabetes, non‑alcoholic steatohepatitis (NASH), alcoholic liver disease and new‑onset type 1 diabetes. The goal is to assess the impact of emerging drugs on liver health, glycaemic control and beta‑cell preservation.

• Semaglutide for improving liver histology in NASH patients
• GLP‑1 receptor agonist combination therapy for advanced fibrosis
• Beta‑cell function preservation with a novel monoclonal antibody in recent type 1 diabetes onset
• Alcohol‑related liver disease treatment with an investigational oral agent
• Evaluation of metabolic dysfunction‑associated steatohepatitis outcomes

The site’s multidisciplinary approach supports over 90 disease indications, fostering innovative metabolic therapies.

A broad oncology portfolio at the hospital addresses cancer across solid tumors and hematologic malignancies. Studies investigate targeted agents, immunotherapy combinations, and personalized regimens for breast, lung, lymphoma and liver cancers, with the aim of extending survival and achieving deeper responses.

• HER2‑positive breast cancer treated with trastuzumab, tucatinib and vinorelbine
• EGFR‑mutant non‑small cell lung cancer after third‑generation TKI progression
• Neoadjuvant atezolizumab plus chemotherapy for triple‑negative breast cancer
• Follicular lymphoma combined with ibrutinib and rituximab
• Relapsed small‑cell lung cancer evaluated with lurbinectedin alone or with irinotecan

The oncology program leverages expertise from 82 investigators to bring cutting‑edge cancer treatments to patients in Spain.

The center’s neurology initiatives focus on headache disorders, epilepsy and multiple sclerosis. Clinical work evaluates preventive antibodies, acute migraine agents, seizure‑reducing compounds and disease‑modifying therapies, seeking to lower attack frequency and improve quality of life.

• CGRP antibody therapy for chronic migraine prevention
• Atogepant for acute treatment of single migraine attacks
• PRAX‑628 to reduce focal seizure frequency in adults
• Remibrutinib compared with teriflunomide for relapsing multiple sclerosis
• Eptinezumab as a preventive option for migraine with medication overuse headache

With a strong focus on patient‑centered outcomes, the site supports both adult and pediatric populations across neurological diseases.

Specialized trials address eye diseases such as diabetic macular edema, thyroid eye disease and non‑infectious uveitis. Investigations aim to improve visual acuity and reduce disease‑related inflammation through novel drug delivery systems and biologic agents.

• OCS‑01 eye drops for diabetic macular edema
• Therapeutic options for thyroid eye disease
• Combination methotrexate and adalimumab for non‑infectious uveitis
• Advanced ocular physiological monitoring technologies
• Evaluation of sub‑retinal hyperreflective material treatments

The ophthalmology program integrates cutting‑edge diagnostics with therapeutic trials, enhancing eye care for the regional population.

The department conducts studies on infectious and immune‑mediated conditions, ranging from bacterial sepsis to chronic viral infections. Research explores shortened antibiotic courses, antiviral nucleic‑acid therapies and immune modulators to improve outcomes and reduce treatment burden.

• Short‑course (7‑day) antibiotic regimen for Pseudomonas aeruginosa bacteremia
• Bepirovirsen for functional cure in chronic hepatitis B
• GSK4532990 assessing liver function improvement in alcohol‑related liver disease
• COVID‑19 therapeutic evaluation in high‑risk patients
• Respiratory syncytial virus infection management in adults

These trials reflect the site’s commitment to addressing emerging infectious threats and chronic viral diseases across Europe.

Focused investigations target musculoskeletal conditions such as knee osteoarthritis and bone lesions associated with Langerhans cell histiocytosis. Studies compare cell‑based therapies, hyaluronic acid controls and novel biologics to restore joint function and reduce pain.

• Allogeneic versus autologous mesenchymal stem cells versus hyaluronic acid for knee osteoarthritis
• Extended continuation therapy for Langerhans cell histiocytosis with bone involvement
• Evaluation of pain reduction strategies after orthopedic surgery
• Investigation of bone‑targeted agents in single‑system LCH
• Assessment of functional outcomes following stem‑cell implantation

The site’s orthopedic research leverages a multidisciplinary team to advance regenerative approaches for degenerative joint disease.